FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Offering improved detection for breast cancer in women with dense breasts as well as enhanced diagnosis of invasive lobular cancer, the AI-powered ProFound Detection Version 4.0 software for digital breast tomosynthesis (DBT) has garnered 510(k) clearance from the Food and Drug Administration (FDA).
ProFound Detection Version 4.0 provides a 50 percent improvement for diagnosing breast cancer in women with dense breasts in comparison to the previous version of the software, according to iCAD, the manufacturer of ProFound Detection Version 4.0.
The newly FDA-cleared ProFound Detection Version 4.0 software leverages artificial intelligence (AI) to provide enhanced detection of breast cancer in women with dense breasts as well as invasive lobular cancer on digital breast tomosynthesis (DBT) in comparison to a previous version of the AI software. (Image courtesty of iCAD.)
In contrast to the third version of the software, iCAD said ProFound Detection Version 4.0 also offers a 60 percent improvement in diagnosis of invasive lobular cancer, a 38 percent improvement in detecting cancer smaller than 1 cm and a 21 percent improvement in identifying invasive breast cancer.
“ProFound Detection Version 4.0 will dramatically improve breast cancer detection,” noted Chirag Parghi, M.D., M.B.A., the chief medical officer at Solis Mammography. “The newest version’s ability to detect subtle invasive cancers, especially within dense breast tissue, addresses one of the biggest challenges in breast imaging today.”
Noting the software’s potential for reducing false positives, iCAD said ProFound Detection Version 4.0 offers a 20 percent reduction in marks related to vascular calcification and a 51 percent reduction in marks related to non-vascular calcification. The software, which will be showcased at the upcoming Radiological Society of North America (RSNA) 2024 Annual Meeting, also enables radiologists to include a prior DBT examination into the AI analysis, according to iCAD.
Recent Videos
Related Content
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025Article
In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Article
Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Article
Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
